Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease
复制标题
DOI：
10.1016/j.neurobiolaging.2005.10.007
复制
发表时间：
2006-12-01
影响因子：
4.2
通讯作者：
Scarpini, Elio
中科院分区：
文献类型：
--
作者：
Galimberti, Daniela;Fenoglio, Chiara;Scarpini, Elio
包括单核细胞趋化蛋白-1（MCP-1）在内的许多趋化因子的上调与阿尔茨海默病（AD）的病理变化相关。新出现的证据表明，炎症事件先于AD的临床发展，因为在轻度认知障碍（MCI）患者中也观察到细胞因子失调。在来自48名MCI受试者、94名AD患者和24名年龄匹配的对照的血清样品中评估MCP-1水平。MCI组和轻度AD组MCP-1水平显著高于对照组，而重度AD组MCP-1水平无显著性差异。通过定量RT-PCR分析评估外周血单个核细胞（PBMC）中的mRNA水平，其高于血清MCP-1水平。此外，在1年的随访中，在MCI转化为AD的受试者亚组中观察到进行性MCP-1降低。MCP-1上调可能是AD发病机制中非常早期的事件，远远早于疾病的临床发作。然而，由于MCP-1可能在具有炎性组分的几种病理中起作用，因此仅与其他分子组合才可能作为早期AD生物标志物。(c)2005年爱思唯尔公司All rights reserved.
Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI).MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usfulness as an early AD biomarker would be possible only in combination with other molecules. (c) 2005 Elsevier Inc. All rights reserved.